Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q3 2022 – Thematic Intelligence
In the Pharmaceuticals industry there were eight M&A deals in Q3 2022 with a deal size greater than $1 billion, compared to four such deals in the previous quarter. The pharmaceuticals industry M&A deals thematic research report provides an overview of merger and acquisition activity globally in Q3 2022 in the pharmaceuticals industry. It also identifies the themes driving the most notable deals announced in Q3 2022 in the pharma industry. The report also offers a comparison on the pharmaceuticals sector deal activity by volume and value on segments such as cross-border vs domestic and public vs private.
Pharmaceuticals Industry M&A Deals: Top Themes
The key themes driving the merger and acquisitions in the pharmaceuticals industry were rare diseases, and orphan designated diseases.
M&A Deals Activity in the Pharmaceuticals Industry by Regions
North America, Europe, China, South & Central America, the Middle East and Africa, and APAC Ex-China are the key regions in the pharmaceuticals industry M&A market. Europe and China reported an increase in deal value in Q3 2022 compared to Q2 2022.
Pharmaceuticals Industry M&A Deals Activity Analysis, by Regions
For more insights on regional analysis of the M&A deals in the pharmaceuticals sector in Q3 2022 , download a free report sample
M&A Deals Activity in the Pharmaceuticals Industry by Sub-Sectors
Immunology, central nervous system, oncology, cardiovascular, infectious disesase, respiratory, dermatology, gastrointestinal, ophthalmology, metabolic disorders, and genetic disooirders are the key sub-sectors in the pharmaceuticals industry M&A deals. Oncology led the M&A market in terms of deal volume in Q1-Q3 2022.
Pharmaceuticals Industry M&A Deals Activity Analysis, by Sub-Sectors
For more insignts on sub-sectors in the pharmaceuticals industry M&A deals, download a free report sample
Top Pharmaceuticals Industry M&A Deals
The key M&A deals in the pharmaceuticals industry in Q3 2022 were:
- In August 2022, Pfizer acquired Global Blood Thereapeutics.
- During the same time, Amgen acquired ChemoCentryx.
- In July 2022, Royalty Pharma acquired a significant stake in Theravance Respiratory Company.
For more insights on pharmaceuticals industry M&A deals, download a free report sample
Market Report Overview
|Top Themes||Rare Diseases, and Orphan Designated Diseases|
|Regional Segments||North America, Europe, China, South and Central America, The Middle East and Africa, and APAC Ex-China|
|Key Sub-sectors||Immunology, Central Nervous System, Oncology, Cardiovascular, Infectious Disesase, Respiratory, Dermatology, Gastrointestinal, Ophthalmology, Metabolic Disorders, and Genetic Disooirders|
- This report provides an overview of merger and acquisition activity globally in Q3 2022 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q3 2022 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Good Works II
Sartorius Stedim Biotech
OMERS Capital Markets
Mayne Pharma Group
Global Blood Therapeutics
Table of Contents
Review of global pharma M&A deals in Q3 2022
Themes driving global pharma M&A deals in Q3 2022
Appendix 1: Deal selection criteria
Appendix 2: Our thematic research methodology
Frequently Asked Questions
The M&A deal value in the pharmaceuticals industry reached $26 billion in Q3 2022.
The key themes driving the merger and acquisition in the pharmaceuticals industry were rare diseases, and orphan designated diseases.
North America, Europe, China, South and Central America, the Middle East and Africa, and APAC Ex-China are the key regions for Pharmaceuticals industry M&A deals.
The key sub-sectors in the pharmaceuticals industry M&A deals are immunology, central nervous system, oncology, cardiovascular, infectious disesase, respiratory, dermatology, gastrointestinal, ophthalmology, metabolic disorders, and genetic disooirders.
Get in touch to find out about our multi-purchase discounts
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.